Altimmune
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH.
CEOVipin K. Garg
CEOVipin K. Garg
Employees59
Employees59
HeadquartersGaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded1997
Founded1997
Employees59
Employees59
ALT Key Statistics
Market cap435.11M
Market cap435.11M
Price-Earnings ratio-3.90
Price-Earnings ratio-3.90
Dividend yield—
Dividend yield—
Average volume3.30M
Average volume3.30M
High today$4.23
High today$4.23
Low today$3.90
Low today$3.90
Open price$3.95
Open price$3.95
Volume2.63M
Volume2.63M
52 Week high$10.88
52 Week high$10.88
52 Week low$2.90
52 Week low$2.90
Stock Snapshot
With a market cap of 435.11M, Altimmune(ALT) trades at $4.17. The stock has a price-to-earnings ratio of -3.90.
During the trading session on 2025-11-15, Altimmune(ALT) shares reached a daily high of $4.23 and a low of $3.90. At a current price of $4.17, the stock is +6.9% higher than the low and still -1.3% under the high.
Trading volume for Altimmune(ALT) stock has reached 2.63M, versus its average volume of 3.3M.
The stock's 52-week range extends from a low of $2.90 to a high of $10.88.
The stock's 52-week range extends from a low of $2.90 to a high of $10.88.
ALT News
TipRanks 4d
Altimmune announces publication of IMPACT Phase 2b trial dataAltimmune (ALT) announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with m...
Analyst ratings
78%
of 9 ratingsBuy
77.8%
Hold
11.1%
Sell
11.1%
People also own
Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.